Who
Michael S. Hearne
Chief Financial Officer
Company insider
Files Form 4 as: Chief Financial Officer, Aurinia Pharmaceuticals; Chief Financial Officer, La Jolla Pharmaceutical Co; Chief Financial Officer, Odonate Therapeutics.
In numbers
- Trades disclosed
- 258
- Buys
- 8
- Sells
- 0
- Bought
- $2.7M
- Sold
- $0
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 30 Nov 2018
- Last trade
- 18 May 2026
- Last filed
- 20 May 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 18 May 2026filed 20 May 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —116,144 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,230 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | AUPH Aurinia Pharmaceuticalsoption or derivative · Biotechnology | SEC FORM 4 Code A | —70,230 at $0.00 | filing |
| 18 May 2026filed 20 May 2026 | AUPH Aurinia PharmaceuticalsBiotechnology | SEC FORM 4 Code A | —116,144 at $0.00 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —100,000 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —169 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —196 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —141 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —134 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —52,191 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —147 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —1,648 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —136 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —118 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —108 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —139 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —127 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —172 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —173 | filing |
| 22 Aug 2022filed 24 Aug 2022 | La Jolla Pharmaceutical Cooption or derivative | SEC FORM 4 Code D | —164 | filing |
News
No headline names them, or the companies they trade most, lately.